TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19947254

Group type: EXPERIMENTAL
Intervention: Coblation-assisted tonsillectomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional dissection tonsillectomy
Number of subjects: 92
Study: 17060250

Group type: EXPERIMENTAL
Intervention: CBT training with supervision
Number of subjects: 20

Group type: COMPARATOR
Intervention: CBT training without supervision (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CBT training with continued supervision
Number of subjects: 20
Study: 12577293

Group type: EXPERIMENTAL
Intervention: Oligodendrogliomas
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-grade oligodendrogliomas
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-grade oligodendrogliomas
Number of subjects: 15
Study: 10619946

Group type: EXPERIMENTAL
Intervention: Urine drainage system with antibacterial device
Number of subjects: 213

Group type: COMPARATOR
Intervention: Urine drainage system without antibacterial device
Number of subjects: 213
Study: 9200094

Group type: EXPERIMENTAL
Intervention: Follow-up visit at 4 weeks (FU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No follow-up visit with instruction sheet (NFU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall satisfaction with care
Number of subjects: 100
Study: 8501455

Group type: EXPERIMENTAL
Intervention: Active placebos
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inert placebos
Number of subjects: 0
Study: 3908509

Group type: EXPERIMENTAL
Intervention: Modified Goeckerman regimen with hydrocortisone valerate cream
Number of subjects: 19

Group type: COMPARATOR
Intervention: Modified Goeckerman regimen with vehicle cream
Number of subjects: 19
Study: 29680006

Group type: EXPERIMENTAL
Intervention: Intraprostatic injections of onabotulinumtoxinA (200 U)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cystoscopy only (Control)
Number of subjects: 43
Study: 26117486

Group type: EXPERIMENTAL
Intervention: Unloader knee brace (adjusted)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Unloader knee brace (unadjusted)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 29
Study: 24193238

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (Group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 106
Study: 22692023

Group type: EXPERIMENTAL
Intervention: Milk with Lactobacillus rhamnosus GG
Number of subjects: 523
Study: 20879867

Group type: EXPERIMENTAL
Intervention: Hand washing
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no hand washing)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Households with index patients aged ≤8 years
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Households with secondary infections
Number of subjects: 90
Study: 18573839

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 12
Study: 16095053

Group type: EXPERIMENTAL
Intervention: Bacterial antigen stimulation (lipopolysaccharides or protein A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 61
Study: 12419751

Group type: COMPARATOR
Intervention: 5-fluorouracil alone (F)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and mitomycin C (FM)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, doxorubicin and mitomycin C (FAM)
Number of subjects: 416
Study: 10599951

Group type: EXPERIMENTAL
Intervention: Deramciclane 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deramciclane 30 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deramciclane 60 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deramciclane (all doses)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7588688

Group type: EXPERIMENTAL
Intervention: 6 days of heat acclimation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 12 days of heat acclimation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control conditions (normal light combat clothing)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NBC protective clothing
Number of subjects: 16
Study: 1945578

Group type: EXPERIMENTAL
Intervention: DTP-PRP-T
Number of subjects: 112

Group type: COMPARATOR
Intervention: DTP-Placebo
Number of subjects: 112
Study: 6289447

Group type: EXPERIMENTAL
Intervention: Prolonged course of chemotherapy (41 weeks) combining adriamycin, methotrexate in high doses followed by folinic acid, vincristine, and cyclophosphamide
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Radiotherapy delivering 20 grays to the lungs
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Short course of chemotherapy (8 weeks) combining adriamycin, methotrexate in high doses, folinic acid and vincristine, associated with irradiation of the lungs
Number of subjects: 156
Study: 31940095

Group type: EXPERIMENTAL
Intervention: Subgaleal drains
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Curved incisions, larger craniotomy, and tumor size
Number of subjects: 150
Study: 30784924

Group type: EXPERIMENTAL
Intervention: Xinkeshu tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29326406

Group type: EXPERIMENTAL
Intervention: Visiting education (90 min) in the 1st week and smartphone application education (10 min) thrice a week in the 2nd and 3rd weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 40
Study: 25534369

Group type: EXPERIMENTAL
Intervention: High dose tDCS
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low dose tDCS
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 99
Study: 24708292

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 23113543

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxaliplatin combined with 5-fluorouracil chemotherapy or Xeloda
Number of subjects: 0
Study: 19778495

Group type: EXPERIMENTAL
Intervention: Adjunctive olanzapine (5 to 20 mg/d)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 202
Study: 17642422

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN) 5 mIU/m2 for 6 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN) 5 mIU/m2 for 6 months plus lamivudine 4 mg/kg/day for 24 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (control group III)
Number of subjects: 49
Study: 15741208

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557

Group type: COMPARATOR
Intervention: Cyclosporin A Microemulsion (CsA-ME)
Number of subjects: 557
Study: 12421063

Group type: EXPERIMENTAL
Intervention: Perceptual matching task with pictures of various objects and scenes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Old-new recognition experiment using the same stimuli as the matching task
Number of subjects: 0
Study: 10347354

Group type: EXPERIMENTAL
Intervention: Resin composite cement
Number of subjects: 48

Group type: COMPARATOR
Intervention: Compomer cement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crown type G (gold alloy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crown type AC (bonding alloy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crown type PC (porcelain)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Crown type PS (porcelain)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Method of cement removal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tooth surface morphology (anatomically grooved vs ungrooved)
Number of subjects: 48
Study: 7493435

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia (2.5 mmol/l)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Avoidance of antecedent hypoglycaemia for 6 days
Number of subjects: 10
Study: 1974493

Group type: EXPERIMENTAL
Intervention: famotidine, 40 mg after the evening meal for 28 days
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ranitidine, 300 mg four times a day for seven days followed by 300 mg at night until day 28
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ranitidine, 300 mg three times a day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ranitidine, 300 mg at night
Number of subjects: 3
Study: 6244414

Group type: EXPERIMENTAL
Intervention: Intravesical neomycin/polymyxin-B
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low dose daily macrocrystals of nitrofurantoin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravesical treatment and oral nitrofurantoin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 64
Study: 31098989

Group type: EXPERIMENTAL
Intervention: Meropenem–vaborbactam (MV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 0
Study: 28807739

Group type: EXPERIMENTAL
Intervention: Faith-enhanced Diabetes Prevention Program (DPP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard Diabetes Prevention Program (DPP)
Number of subjects: 221
Study: 25991758

Group type: EXPERIMENTAL
Intervention: Protocolised algorithm using stroke volume variation to guide fluid administration
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 23471488

Group type: EXPERIMENTAL
Intervention: Active pellets (5 g, 47% lauric acid by weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21452269

Group type: EXPERIMENTAL
Intervention: Wegener's Granulomatosis Etanercept Trial (WGET) cohort
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Diastolic hypertension
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Positive proteinase 3 (PR3) ANCA status
Number of subjects: 535

Group type: COMPARATOR
Intervention: EUVAS trials
Number of subjects: 535
Study: 19351658

Group type: EXPERIMENTAL
Intervention: Intranasal 350 microg 17beta-estradiol + 550 microg norethisterone
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Intranasal 350 microg 17beta-estradiol + 50 or 175 microg norethisterone
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Intranasal regimens
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Oral 2 mg 17beta-estradiol + 1 mg norethisterone
Number of subjects: 1741
Study: 18006769

Group type: EXPERIMENTAL
Intervention: ABT‐510 10 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABT‐510 100 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14602190

Group type: EXPERIMENTAL
Intervention: GL (Gelucire 44/14 and Labrasol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CD (piroxicam:beta‐cyclodextrin complex)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PP (pure piroxicam)
Number of subjects: 8
Study: 10872552

Group type: EXPERIMENTAL
Intervention: beta-blockade
Number of subjects: 596

Group type: COMPARATOR
Intervention: hypertensive patients
Number of subjects: 596

Group type: COMPARATOR
Intervention: normotensive controls
Number of subjects: 596
Study: 9359726

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefaclor for 10 days
Number of subjects: 100
Study: 8491498

Group type: EXPERIMENTAL
Intervention: Random zero sphygmomanometer
Number of subjects: 1356
Study: 3897451

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemagglutination inhibition (HAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complement fixation (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutralization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 0
Study: 31875661

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination method
Number of subjects: 10
Study: 30378311

Group type: EXPERIMENTAL
Intervention: EGFR-TKIs plus Traditional Chinese Medicine (TCM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: EGFR-TKIs
Number of subjects: 59
Study: 26944733

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice a day (D150)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran 110 mg twice a day (D110)
Number of subjects: 0
Study: 24189245

Group type: EXPERIMENTAL
Intervention: GSK1322322 (1,500 mg, twice daily intravenous dosing for 4 days)
Number of subjects: 0
Study: 21712704

Group type: EXPERIMENTAL
Intervention: GSUC (sealed gauze dressing)
Number of subjects: 87

Group type: COMPARATOR
Intervention: VAC (vacuum-assisted closure device)
Number of subjects: 87
Study: 20229001

Group type: COMPARATOR
Intervention: Fentanyl (group F)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil (group R)
Number of subjects: 40
Study: 18387026

Group type: EXPERIMENTAL
Intervention: Smoking prevention curriculum implementation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Year long class schedule
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High teacher self-efficacy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Perceived curriculum complexity
Number of subjects: 62
Study: 16165400

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg twice daily for 9 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12865102

Group type: EXPERIMENTAL
Intervention: Levalbuterol (2.5 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Albuterol (10 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 27
Study: 10805059

Group type: EXPERIMENTAL
Intervention: Selegiline treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8644690

Group type: EXPERIMENTAL
Intervention: 20 g FOS/d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 12
Study: 2004542

Group type: EXPERIMENTAL
Intervention: Nimesulide oral suspension, 5 mg/kg/day divided into 3 daily doses for 5 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6440445

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30873696

Group type: COMPARATOR
Intervention: PFMX (control group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PFMX plus Pfilates and Hypopressives (APFX)
Number of subjects: 37
Study: 29774477

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g q8h for adults and 50 mg/kg q8h for children)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Cefoperazone/sulbactam plus amikacin (CS + A) (2 g q8h for adults and 50 mg/kg q8h for children plus amikacin 15 mg/kg once a day)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Cefoperazone/sulbactam plus amikacin (CS + A)
Number of subjects: 175
Study: 27605407

Group type: EXPERIMENTAL
Intervention: Stable emulsion (E1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unstable emulsion (E4)
Number of subjects: 21
Study: 23901043

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks plus intranasal budesonide for 12 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: No steroid treatment (Control)
Number of subjects: 89
Study: 22083515

Group type: EXPERIMENTAL
Intervention: Simplified Pelvic Organ Prolapse Quantification (POP-Q) system
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Weighted kappa statistic
Number of subjects: 511
Study: 20409751

Group type: COMPARATOR
Intervention: D1 lymphadenectomy
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 711
Study: 18310867

Group type: EXPERIMENTAL
Intervention: Antibiotics immediately following surgery and for at least seven days thereafter (Group-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: One gram of cephazoline injected intravenously before anesthesia and continued for 24 hours after surgery (Group-2)
Number of subjects: 100
Study: 16085556

Group type: EXPERIMENTAL
Intervention: Daily serum C-reactive protein (CRP) levels measured during the 3 week period following treatment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CRP levels cut-off point of 100 mg/l
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CRP velocity cut-off point of 15 mg/l/day
Number of subjects: 104
Study: 11818372

Group type: EXPERIMENTAL
Intervention: Progressive-addition lenses
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single-vision lenses
Number of subjects: 469
Study: 10068969

Group type: EXPERIMENTAL
Intervention: Ketoprofen (1 mg W kg‐1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg W kg‐1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Saline (0.1 ml W kg‐1)
Number of subjects: 91
Study: 8657963

Group type: EXPERIMENTAL
Intervention: Dry boldo extract (2.5 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 12
Study: 1646369

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment for 9 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (untreated PTH-NANB patients)
Number of subjects: 19
Study: 6271838

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 52

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 52
Study: 30765762

Group type: EXPERIMENTAL
Intervention: Bushen Yijing Fang (BSYJF) with calcium carbonate 300 mg daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo with calcium carbonate 300 mg daily
Number of subjects: 140
Study: 27858686

Group type: EXPERIMENTAL
Intervention: Physical examination by raters A, B, C, and D
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical examination parameters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drop test positive
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Digital interspinous pressure test positive
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pooled parameters of physical examination suggestive of SI joint pain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pooled parameters of physical examination suggestive of facet joint or disc pain
Number of subjects: 100
Study: 25742535

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (behavioral lifestyle intervention program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed control group (no immediate intervention)
Number of subjects: 0
Study: 23538757

Group type: EXPERIMENTAL
Intervention: Temperature at 37ºC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Temperature at 25ºC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Storage medium in distilled water
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Storage medium dry
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Specimen dimensions 10×2×2 mm
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Specimen dimensions 25×2×2 mm
Number of subjects: 80
Study: 21550158

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel applied to the socket of the third molar
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 60
Study: 19117316

Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (four-dose intralesional injection series at eight-week intervals)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (for macrocystic LM)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (for mixed macrocystic-microcystic LM)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (for microcystic LM)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Delayed treatment group (observational controls)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: OK-432 immunotherapy vs historical surgical data on LM
Number of subjects: 182
Study: 17826452

Group type: EXPERIMENTAL
Intervention: Leisure education program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (home visits)
Number of subjects: 62
Study: 15100340

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 11740145

Group type: EXPERIMENTAL
Intervention: hCG (500 IU/week if <2 years or 1,000 IU/week if >2 years for 6 weeks)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: hCG + hMG (hCG as in group 1 + hMG 75 IU/week for 6 weeks)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: GnRH (1,200 microg/daily for 28 days)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: GnRH + hCG (1,200 microg/daily for 28 days + 1,500 IU/week for 3 weeks)
Number of subjects: 155

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 155
Study: 10707784

Group type: EXPERIMENTAL
Intervention: t(14;18) translocation detection in healthy individuals
Number of subjects: 264

Group type: COMPARATOR
Intervention: t(14;18) translocation detection in family members of NHL patients
Number of subjects: 264
Study: 9174522

Group type: EXPERIMENTAL
Intervention: Wrist guards
Number of subjects: 2

Group type: COMPARATOR
Intervention: No wrist guards (control)
Number of subjects: 2
Study: 1487229

Group type: EXPERIMENTAL
Intervention: 1 g propacetamol HCl given intravenously over a 15‐min period
Number of subjects: 12

Group type: COMPARATOR
Intervention: 500 mg paracetamol given orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 g propacetamol HCl given as a 15‐min infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 g propacetamol HCl given as a 2‐min bolus injection
Number of subjects: 12
Study: 2987102

Group type: EXPERIMENTAL
Intervention: Entire tumor or ten blocks examined in a blinded and randomized fashion using the revised (1981) WHO classification
Number of subjects: 100